One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
New guidelines on adult congenital heart disease, the fantastic four in the treatment of heart failure, and also what happened in the last year in heart failure and valvular heart disease
Filippo Crea
doi : 10.1093/eurheartj/ehab044
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 551–554
‘Corona’ versus ‘coronary’
Roberto Ferrari, MD, Claudio Rapezzi, Paolo Cimaglia
doi : 10.1093/eurheartj/ehaa897
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 555–557
Heart Failure 2019
Plamen Gatzov, MD, Jean-Jacques Monsuez, MD, Gergely Agoston, MD, Michael Aschermann, MD, Hala Mahfouz Badran, MD, Ariel Cohen, MD, Kurt Huber, MD, Evgeny Shlyakhto, MD, Dilek Ural, MD, Ignacio Ferreira-Gonzalez, MD, Fernando Alfonso, MD
doi : 10.1093/eurheartj/ehaa918
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 557–559
The right ventricle in COVID-19 patients
Mohammad Amin Shahrbaf, MD, Mohammadreza Tabary, MD, Isa Khaheshi, MD
doi : 10.1093/eurheartj/ehaa832
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 559–560
A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine?
Giovanna Liuzzo, MD, PhD, FESC, Carlo Patrono, MD, FESC
doi : 10.1093/eurheartj/ehaa1064
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 561–562
2020 ESC Guidelines for the management of adult congenital heart disease: The Task Force for the management of adult congenital heart disease of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Adult Congenital Heart Disease (ISACHD)
Helmut Baumgartner, Julie De Backer, Sonya V Babu-Narayan, Werner Budts, Massimo Chessa, Gerhard-Paul Diller, Bernard lung, Jolanda Kluin, Irene M Lang, Folkert Meijboom, Philip Moons, Barbara J M Mulder, Erwin Oechslin, Jolien W Roos-Hesselink, Markus Schwerzmann, Lars Sondergaard, Katja Zeppenfeld, ESC Scientific Document Group
doi : 10.1093/eurheartj/ehaa554
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 563–645
The year in cardiovascular medicine 2020: valvular heart disease
Javier Bermejo, Andrea Postigo, Helmut Baumgartner
doi : 10.1093/eurheartj/ehaa1060
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 647–656
The year in cardiovascular medicine 2020: heart failure and cardiomyopathies
Héctor Bueno, Brenda Moura, Patrizio Lancellotti, Johann Bauersachs
doi : 10.1093/eurheartj/ehaa1061
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 657–670
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Joao Pedro Ferreira, Stuart J Pocock, Hans-Peter Brunner-La Rocca, Stefan Janssens, Hiroyuki Tsutsui, Jian Zhang, Martina Brueckmann, Waheed Jamal, Daniel Cotton, Tomoko Iwata, Janet Schnee, Faiez Zannad, for the EMPEROR-Reduced Trial Committees and Investigators
doi : 10.1093/eurheartj/ehaa968
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 671–680
We evaluated the influence of sacubitril/valsartan on the effects of sodium-glucose cotransporter 2 (SGLT2) inhibition with empagliflozin in patients with heart failure and a reduced ejection fraction.
Heart failure drug treatment: the fantastic four
Johann Bauersachs
doi : 10.1093/eurheartj/ehaa1012
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 681–683
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial
John G F Cleland, Jo?o Pedro Ferreira, Beatrice Mariottoni, Pierpaolo Pellicori, Joe Cuthbert, Job A J Verdonschot, Johannes Petutschnigg, Fozia Z Ahmed, Franco Cosmi, Hans-Peter Brunner La Rocca, Mamas A Mamas, Andrew L Clark, Frank Edelmann, Burkert Pieske, Javed Khan, Ken McDonald, Philippe Rouet, Jan A Staessen, Blerim Mujaj, Arantxa Gonz?lez, Javier Diez, Mark Hazebroek, Stephane Heymans, Roberto Latini, Stéphanie Grojean, Anne Pizard, Nicolas Girerd, Patrick Rossignol, Tim J Collier, Faiez Zannad, the HOMAGE Trial Committees and Investigators
doi : 10.1093/eurheartj/ehaa758
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 684–696
To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure.
Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities
Bertram Pitt, James Brian Byrd
doi : 10.1093/eurheartj/ehaa765
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 697–699
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes
William T Abraham, JoAnn Lindenfeld, Piotr Ponikowski, Piergiuseppe Agostoni, Javed Butler, Akshay S Desai, Gerasimos Filippatos, Jacek Gniot, Michael Fu, Lars Gullestad, Jonathan G Howlett, Stephen J Nicholls, Josep Redon, Isabelle Schenkenberger, José Silva-Cardoso, Stefan St?rk, Jerzy Krzysztof Wranicz, Gianluigi Savarese, Martina Brueckmann, Waheed Jamal, Matias Nordaby, Barbara Peil, Ivana Ritter, Anastasia Ustyugova, Cordula Zeller, Afshin Salsali, Stefan D Anker
doi : 10.1093/eurheartj/ehaa943
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 700–710
The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in heart failure (HF) with reduced and preserved ejection fraction (EF), with and without type 2 diabetes (T2D), reporting, for the first time, the effects of sodium-glucose co-transporter-2 inhibition in HF with preserved EF (HFpEF).
EMPEROR-REDUCED reigns while EMPERIAL whimpers
Mark C Petrie, Matthew M Lee, Ninian N Lang
doi : 10.1093/eurheartj/ehaa965
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 711–714
On risk stratification and its paradoxes
Pedro Brugada
doi : 10.1093/eurheartj/ehaa839
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 715–716
Rathke's cleft cyst induced cardiac arrest
Shinnosuke Sawano, Atsuko Nakayama, Hiroyuki Morita, Issei Komuro
doi : 10.1093/eurheartj/ehaa913
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Page 714
A patient with rapid worsening dyspnoea during Covid-19 pandemic
Andrea Baggiano, Stefania Rizzo, Cristina Basso, Gianluca Pontone
doi : 10.1093/eurheartj/ehaa988
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Pages 717–718
Erratum to: Development and validation of two SCORE-based cardiovascular risk prediction models for Eastern Europe: a multicohort study
doi : 10.1093/eurheartj/ehaa875
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Page 670,
Corrigendum to: Clinical presentation, management and 6-month outcomes in women with peripartum cardiomyopathy, an ESC EORP registry
doi : 10.1093/eurheartj/ehaa940
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Page 680
Corrigendum to: Reduction of hospitalizations for myocardial infarction in Italy in the Covid-19 era
doi : 10.1093/eurheartj/ehaa976
European Heart Journal, Volume 42, Issue 6, 7 February 2021, Page 683
